Probe of Danish Pharmaceuticals Group Lundbeck Started by EU

As confirmed by the European Union antitrust officials, the agency has started an investigation into the possible anti-competitive behavior which is being displayed by the Danish drugs manufacturer Lundbeck, but the company is adamant that no laws have been broken by it.

The European Union, which is the executive arm of the EU, on Thursday shared that it would be investigating into the workings of the international drug development group for possible breaches of EU rules on some business practices that are prohibited, in addition to potential abuse of a strong and dominant market position.

As per the regulator, Lundbeck, the original developer of Citalopram, a popular and widely used anti-depressant, might have hindered that entry of a generic form of the medicine in markets across Europe.

"The Commission in particular intends to investigate unilateral behaviour and agreements by Lundbeck which may hinder the entry of generic Citalopram into markets in the European Economic Area", the agency said.

On its end, the company has said that it is co-operating with the investigation completely. "We have nothing to hide. Lundbeck is confident that the group has complied with all relevant national and EU competition legislation", the company said.